+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID05963698

Evaluating WATCHMAN Device Versus Standard Care to Prevent Stroke in High-Risk Atrial Fibrillation Patients

Led by Hamilton Health Sciences Corporation · Updated on 2026-09-18

4000

Participants Needed

150

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether catheter-based endovascular left atrial appendage occlusion can reduce the risk of ischemic stroke or systemic embolism in people with atrial fibrillation who remain at high stroke risk despite ongoing oral anticoagulation treatment. This multicenter, open-label, randomized controlled trial with blinded assessment aims to clarify the benefit of this intervention for stroke prevention in this population. Participants are randomly assigned to receive either the WATCHMAN device for left atrial appendage occlusion or standard medical care without this procedure. The WATCHMAN device is placed via a catheter to close off the left atrial appendage. Participants continue their oral anticoagulation as prescribed. The study expects an average follow-up of about 4 years, with the primary analysis conducted after 265 stroke or embolism events have occurred. During the study, participants undergo regular monitoring and assessments to track the occurrence of ischemic stroke, systemic embolism, and other cardiovascular events. Cognitive function is also evaluated using the Montreal Cognitive Assessment. Safety and mortality outcomes will be recorded throughout the trial duration. Participants are followed for the full study period estimated at around 4 years to gather comprehensive data on the interventions effects.

CONDITIONS

Brief Title

The Fourth Left Atrial Appendage Occlusion Study

Research Team

P

Program Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here